-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
New York State Common Retirement Fund Cuts Stock Position in Orchard Therapeutics Plc (NASDAQ:ORTX)
New York State Common Retirement Fund Cuts Stock Position in Orchard Therapeutics Plc (NASDAQ:ORTX)
New York State Common Retirement Fund lessened its position in Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) by 66.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 323,397 shares of the company's stock after selling 632,861 shares during the quarter. New York State Common Retirement Fund's holdings in Orchard Therapeutics were worth $230,000 at the end of the most recent reporting period.
Separately, SG Americas Securities LLC purchased a new stake in Orchard Therapeutics during the 4th quarter worth about $858,000. Institutional investors and hedge funds own 56.47% of the company's stock.
Get Orchard Therapeutics alerts:Analysts Set New Price Targets
Separately, Barclays cut their price target on Orchard Therapeutics from $6.00 to $4.00 in a report on Friday, May 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Orchard Therapeutics has an average rating of "Hold" and a consensus target price of $7.75.
Orchard Therapeutics Price Performance
Shares of NASDAQ ORTX opened at $0.56 on Monday. The stock's 50-day moving average is $0.59 and its two-hundred day moving average is $0.67. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.24 and a quick ratio of 4.24. Orchard Therapeutics plc has a 1-year low of $0.41 and a 1-year high of $3.18. The company has a market cap of $70.80 million, a price-to-earnings ratio of -0.42 and a beta of 0.80.Orchard Therapeutics Company Profile
(Get Rating)
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration.
Further Reading
- Get a free copy of the StockNews.com research report on Orchard Therapeutics (ORTX)
- 2 EV Suppliers Powering To Gains After Raising Views
- Applied Materials Results Show A Slowing Semiconductor Market
- MarketBeat: Week in Review 8/15 – 8/19
- Near-Term Headwinds Present An Opportunity In Ross Stores
- Apple's Stock Could Be On The Verge Of Another 30% Rally
Want to see what other hedge funds are holding ORTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating).
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
New York State Common Retirement Fund lessened its position in Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) by 66.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 323,397 shares of the company's stock after selling 632,861 shares during the quarter. New York State Common Retirement Fund's holdings in Orchard Therapeutics were worth $230,000 at the end of the most recent reporting period.
根据纽约州共同退休基金提交给美国证券交易委员会的最新文件，该基金在第一季度减持了Orchard Treateutics Plc(纳斯达克：ORTX-GET评级)66.2%的股份。该公司在本季度出售了632,861股后，持有323,397股该公司股票。在最近一个报告期结束时，纽约州共同退休基金在Orchard Treeutics持有的股份价值23万美元。
Separately, SG Americas Securities LLC purchased a new stake in Orchard Therapeutics during the 4th quarter worth about $858,000. Institutional investors and hedge funds own 56.47% of the company's stock.
另外，SG America Securities LLC在第四季度购买了Orchard Treeutics的新股份，价值约85.8万美元。机构投资者和对冲基金持有该公司56.47%的股票。
Analysts Set New Price Targets
分析师设定新的价格目标
Separately, Barclays cut their price target on Orchard Therapeutics from $6.00 to $4.00 in a report on Friday, May 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Orchard Therapeutics has an average rating of "Hold" and a consensus target price of $7.75.
另外，巴克莱在5月13日星期五的一份报告中将Orchard Treeutics的目标价从6.00美元下调至4.00美元。一名投资分析师对该股的评级为卖出，两名分析师给出了持有评级，三名分析师给出了买入评级。根据MarketBeat的数据，Orchard Treeutics的平均评级为“持有”，共识目标价为7.75美元。
Orchard Therapeutics Price Performance
果园治疗药物性价比
Orchard Therapeutics Company Profile
果园治疗公司简介
(Get Rating)
(获取评级)
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration.
Orchard Treateutics公司是一家生物制药公司，在英国、欧盟和美国开发针对严重和危及生命的罕见疾病的基因疗法。该公司的基因疗法寻求将患者的造血干细胞转化为基因修饰的细胞药物产品，通过单一给药来治疗患者的疾病。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Orchard Therapeutics (ORTX)
- 2 EV Suppliers Powering To Gains After Raising Views
- Applied Materials Results Show A Slowing Semiconductor Market
- MarketBeat: Week in Review 8/15 – 8/19
- Near-Term Headwinds Present An Opportunity In Ross Stores
- Apple's Stock Could Be On The Verge Of Another 30% Rally
- 免费获取StockNews.com关于Orchard Treeutics(ORTX)的研究报告
- 2家电动汽车供应商在提出意见后上涨
- 应用材料公司业绩显示半导体市场放缓
- MarketBeat：回顾中的一周8/15-8/19
- 近期逆风为Ross Stores带来机遇
- 苹果股价可能再次上涨30%
Want to see what other hedge funds are holding ORTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating).
想看看其他对冲基金持有哪些ORTX吗？访问HoldingsChannel.com获取Orchard Treeutics Plc(纳斯达克代码：ORTX-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《果园治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收Orchard Treeutics和相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧